Organization (Industry)
Summit Therapeutics Inc.
ClinicalTrials.gov lists Summit Therapeutics Inc. as lead sponsor of 12 trials. It has 15 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 11 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 13 in 2026 and about 13 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 2 trials are registered to start in 2027 or later.
This page covers Summit Therapeutics Inc.: 12 lead-sponsored trials and 1 legal-entity registration.
Disease areas (37)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 10 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Colorectal Neoplasms | 5 |
| Clostridium Infections | 4 |
| Head and Neck Neoplasms | 3 |
Showing 5 of 37 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 11 |
| 2025 | 14 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 1 |
| 2019 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 2 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (15)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Pembrolizumab Injection | Carcinoma, Non-Small-Cell Lung | Phase 3 | 2 |
| Pembrolizumab Injection | Lung Neoplasms | Phase 3 | 2 |
| Ivonescimab (SMT112 or AK112) Injection | Carcinoma, Non-Small-Cell Lung | Phase 3 | 2 |
| Ivonescimab (SMT112 or AK112) Injection | Lung Neoplasms | Phase 3 | 2 |
| Drug: Bevacizumab Injection | Colorectal Neoplasms | Phase 3 | 1 |
Showing 5 of 15 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| VANCOMYCIN | 3 |
| Enfortumab Vedotin | 1 |
| PEMBROLIZUMAB | 1 |
| Fidaxomicin | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 3 hit target (n=3) | 3 of 4 on time (n=4) |
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 1 |
| Expert opinion on investigational drugs | 1 |
| PloS one | 1 |
| The Journal of antimicrobial chemotherapy | 1 |
| The Lancet. Infectious diseases | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 17 | 1 | 2025-06-03 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | not reported | -1,079,586,000 | 537,674,000 |
| 2024 | 0 | -221,315,000 | 150,777,000 |
| 2023 | 0 | -614,928,000 | 59,471,000 |
| 2022 | 705,000 | -78,782,000 | 51,999,000 |
| 2021 | 1,809,000 | -88,602,000 | 85,352,000 |
| 2020 | 860,000 | -52,697,000 | 53,274,000 |
| 2019 | 57,088,000 | 10,869,000 | 52,003,000 |
| 2018 | 16,388,843 | -26,728,664 | 38,424,941 |
| 2017 | 2,964,655 | -27,498,981 | 24,386,350 |
| 2016 | 0 | -26,585,330 | 22,253,678 |
Showing 10 of 11 fiscal years.
Financing and grant events (58)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-23 | ATM offering | not disclosed | Sec extracted |
| 2026-06-10 | Public offering | not disclosed | Sec extracted |
| 2026-06-02 | ATM offering | not disclosed | Sec extracted |
| 2025-10-29 | Follow-on offering | 502,437,990 | Edgar offerings |
| 2025-10-21 | Private placement | not disclosed | Sec extracted |
Showing 5 of 58 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Memorial Sloan Kettering Cancer Center | Co sponsors trial with | 4 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 3 |
| Mass General Brigham | Co sponsors trial with | 1 |
| Belgian Group of Digestive Oncology | Co sponsors trial with | 1 |
| Intergroupe Francophone de Cancérologie Thoracique | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (115)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-02-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-14 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 115 events.
Biomarker capability evidence (291)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AGA | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 291 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.